MicroRNA-153 functions as a tumor suppressor in gastric cancer via targeting Kruppel-like factor 5.

Exp Ther Med

Department of Colorectal Anal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.

Published: August 2018

Various microRNAs (miRs) have been demonstrated to serve important roles in gastric cancer (GC). miR-153 in particular has been reported to serve a suppressive role in GC; however, the underlying mechanism remains unclear. In the present study Reverse transcription-quantitative polymerase chain reaction and western blot analysis were used to examine the mRNA and protein expression of Kruppel-like factor 5. An MTT, wound healing and transwell assay were used to study cell proliferation, migration and invasion, respectively. In the present study, quantitative polymerase chain reaction data indicated that miR-153 was significantly downregulated in GC tissues compared with the adjacent non-tumor tissues. In addition, the reduced expression of miR-153 was significantly associated with GC aggressiveness and poor prognosis of patients. The expression of miR-153 was also reduced in GC cell lines, including KATO III, NCI-N87, SNU-16 and SNU-5, when compared with normal gastric epithelial GES-1 cells. Overexpression of miR-153 in the GC SNU-5 cells by miR-153 mimic transfection significantly inhibited the cell proliferation, migration and invasion. Furthermore, KLF5 was identified as a target gene of miR-153 in SNU-5 cells by bioinformatics prediction. It was observed that KLF5 was significantly upregulated in GC tissues and cell lines, and its expression was negatively regulated by miR-153 in SNU-5 cells. Overexpression of KLF5 impaired the suppressive effects of miR-153 on the proliferation, migration and invasion of SNU-5 cells. In conclusion, the present study demonstrated that miR-153 serves a tumor suppressive role in GC, at least partly, through directly targeting KLF5, thus highlighting the clinical significance of miR-153 in GC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090467PMC
http://dx.doi.org/10.3892/etm.2018.6226DOI Listing

Publication Analysis

Top Keywords

snu-5 cells
16
proliferation migration
12
migration invasion
12
mir-153 snu-5
12
mir-153
11
gastric cancer
8
kruppel-like factor
8
suppressive role
8
polymerase chain
8
chain reaction
8

Similar Publications

SBL-JP-0004: A promising dual inhibitor of JAK2 and PI3KCD against gastric cancer.

Oncol Res

December 2024

Department of Pathology, College of Medicine, King Khalid University, Abha, 62521, Saudi Arabia.

Background: Gastric cancer (GC) remains a global health burden and is often characterized by heterogeneous molecular profiles and resistance to conventional therapies. The phosphoinositide 3-kinase and PI3K and Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathways play pivotal roles in GC progression, making them attractive targets for therapeutic interventions.

Methods: This study applied a computational and molecular dynamics simulation approach to identify and characterize SBL-JP-0004 as a potential dual inhibitor of JAK2 and PI3KCD kinases.

View Article and Find Full Text PDF

Capmatinib and savolitinib, selective inhibitors, are widely used to treat various -positive cancers. In this study, we aimed to determine the effects of these inhibitors on -amplified gastric cancer (GC) cells. Methods: After screening 37 GC cell lines, the following cell lines were found to be -positive with copy number variation >10: SNU-620, ESO51, MKN-45, SNU-5, and OE33 cell lines.

View Article and Find Full Text PDF

Gastric cancer metastasis is a major cause of poor prognosis. Our previous research showed that methionine restriction (MR) lowers the invasiveness and motility of gastric carcinoma. In this study, we investigated the particular mechanisms of MR on gastric carcinoma metastasis.

View Article and Find Full Text PDF

Gastric adenocarcinoma typically presents with advanced stage when inoperable. Chemotherapy options include non-targeted and toxic agents, leading to poor 5-year patient survival outcomes. Small molecule ONC201/TIC10 (TRAIL-Inducing Compound #10) induces cancer cell death via ClpP-dependent activation of the integrated stress response (ISR) and up-regulation of the TRAIL pathway.

View Article and Find Full Text PDF
Article Synopsis
  • * This study used advanced computational methods to screen a library of small molecules, identifying compound C3 as a promising dual inhibitor of both EGFR and HER2 kinases, displaying effective binding and inhibition properties.
  • * Compound C3 demonstrated strong inhibitory effects on cancer cells with minimal potential side effects, suggesting it could be a viable option for gastric cancer treatment, but further testing is necessary.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!